Saladax Biomedical Revenue and Competitors

Bethlehem, PA USA

Location

$54.9M

Total Funding

Biotech

Industry

Estimated Revenue & Valuation

  • Saladax Biomedical's estimated annual revenue is currently $5.3M per year.(i)
  • 0
  • Saladax Biomedical's total funding is $54.9M.

Employee Data

    00

Saladax Biomedical's People

NameTitleEmail/Phone
1
PRESIDENT & CEOReveal Email/Phone
2
Chief Commercial Officer (CCO)Reveal Email/Phone
3
VP, R&D and OperationsReveal Email/Phone
4
SVP, Development/StraegistReveal Email/Phone
5
Chief Operations OfficerReveal Email/Phone
6
Manager OperationsReveal Email/Phone
7
Sales Development RepresentativeReveal Email/Phone
8
President and CEOReveal Email/Phone
9
Dir STRATEGIC ACCOUNTSReveal Email/Phone
10
Research FellowReveal Email/Phone
Competitor NameRevenueNumber of EmployeesEmployee GrowthTotal FundingValuation
#1
$1.6M100%N/AN/A
#2
$4M2613%N/AN/A
#3
$0.9M6-14%N/AN/A
#4
$1.1M70%N/AN/A
#5
$10.9M703%N/AN/A
#6
$0.7M929%N/AN/A
#7
$4M26-16%N/AN/A
#8
$1.7M1122%N/AN/A
#9
$7.6M492%N/AN/A
#10
$1.6M100%N/AN/A
Add Company

What Is Saladax Biomedical?

Saladax is a personalized medicine diagnostics company that has developed immunoassay technology for dose management of chemotherapy agents. Saladax assays are evidence-based tools that help guide the clinician in providing effective and safe drug therapy to individual patients. Most cancer drugs have a narrow therapeutic index and a dose limiting toxicity profile that make these drugs ideal candidates for dose management through the measurement of drug concentrations in blood. These simple blood tests enable an oncologist to optimize dosing for target drug levels to achieve optimal balance of efficacy and toxicity, where the loss of this balance can have devastating effects on patients

keywords:N/A

$54.9M

Total Funding

N/A

Number of Employees

$5.3M

Revenue (est)

N/A

Employee Growth %

N/A

Valuation

N/A

Accelerator

Saladax Biomedical News

2022-04-13 - Saladax Biomedical Expanding Access to Antipsychotic Drug ...

... firm Saladax Biomedical is looking to change that with an agreement announced last month with Danaher subsidiary Beckman Coulter.

2022-04-06 - Saladax Biomedical, Inc. Acquires Intellectual Property ...

Saladax Biomedical, Inc. Acquires Intellectual Property Portfolio for Antipsychotic Drug Tests. April 05, 2022 09:05 AM Eastern Daylight Time.

2022-03-22 - Saladax Biomedical, Inc. Announces Global Distribution ...

Saladax Biomedical, Inc. Announces Global Distribution Agreement With Beckman Coulter, Inc. for Antipsychotic Drug Tests ... BETHLEHEM, Pa.--(...

2018-06-26 - Saladax Signs Licensing Agreement with Janssen for Antipsychotic Drug Testing Patents

BETHLEHEM, Pa.–(BUSINESS WIRE)–June 26, 2018– Saladax Biomedical, Inc., a diagnostics company providing kits to measure drug blood levels for adherence and medication management, has signed a license agreement with Janssen Pharmaceutica, NV, one of the Janssen Pharmaceutical Companies of Johnso ...

2013-03-05 - Saladax Biomedical Receives $22.4M Strategic Equity Investment

Saladax Biomedical, Inc., a Bethlehem, Pennsylvania-based company developing and commercializing novel diagnostic assays, received a $22.4m strategic equity investment. The backer was Shanghai Fosun Pharmaceutical Co., Ltd. (Fosun Pharma: 600196.SH), a pharmaceutical and healthcare company in t ...

Company NameRevenueNumber of EmployeesEmployee GrowthTotal Funding
#1
$134.9M0N/AN/A
#2
$84M0N/AN/A
#3
$0.1M1-50%N/A
#4
$0.1M10%N/A
#5
$0.2M2N/AN/A